<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0011">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Han</surname>
    <given-names>L</given-names>
   </name>, 
   <name name-style="western">
    <surname>Yuan</surname>
    <given-names>B</given-names>
   </name>, 
   <name name-style="western">
    <surname>Shimada</surname>
    <given-names>R</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hayashi</surname>
    <given-names>H</given-names>
   </name>, 
   <name name-style="western">
    <surname>Si</surname>
    <given-names>N</given-names>
   </name>, 
   <name name-style="western">
    <surname>Zhao</surname>
    <given-names>HY</given-names>
   </name>, 
   <name name-style="western">
    <surname>Bian</surname>
    <given-names>B</given-names>
   </name>, 
   <name name-style="western">
    <surname>Takagi</surname>
    <given-names>N.</given-names>
   </name>
  </person-group>
  <year>2018</year>
  <article-title>Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87</article-title>. 
  <source>Int J Oncol</source>. 
  <volume>53</volume>:
  <fpage>2488</fpage>â€“
  <lpage>2502</lpage>.
  <pub-id pub-id-type="pmid">30272276</pub-id>
 </mixed-citation>
</ref>
